SCHEMBL7825892

SCHEMBL7825892

CCC1=CCCCN1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8135537 0.86
SCHEMBL7826998 0.76 INMT (0.34)
SCHEMBL27400933 0.75 HRH3 (0.33)
SCHEMBL7831654 0.73
SCHEMBL7837916 0.73 INMT (0.33)
SCHEMBL19214892 0.72
SCHEMBL25951688 0.71
Trifluoromethanesulfonic Acid SCHEMBL29252674 0.69 CHRNB2 (0.35)
SCHEMBL24426136 0.68
SCHEMBL4572644 0.67 CHRNB2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3608312-B1 SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF XIAMEN VIVOHEALTHS TECH CO LTD (CN) 2024-06-26 EP disclosed
EP-1602362-B1 DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE TAKEDA PHARMACEUTICAL (JP) 2016-09-28 EP disclosed
US-20160128945-A1 CONTROLLED RELEASE PREPARATION TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
US-20160128945-A1 CONTROLLED RELEASE PREPARATION TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
EP-2275088-B1 Method for producing granules TAKEDA PHARMACEUTICAL (JP) 2015-09-02 EP disclosed
US-9011926-B2 Method for producing granules TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-21 US disclosed
US-9011926-B2 Method for producing granules TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-21 US disclosed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
US-20150072015-A1 METHOD FOR PRODUCING GRANULES TAKEDA PHARMACEUTICAL (JP) 2015-03-12 US disclosed
WO-2008130395-A2 DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS UNIVERSITY OF FLORIDA (US) 2008-10-30 WO disclosed
US-7410981-B2 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-12 US disclosed
US-7410981-B2 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-12 US disclosed
US-20080138427-A1 Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 TAKEDA PHARMACEUTICAL COMPANY (JP) 2008-06-12 US disclosed
US-20080138427-A1 Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 TAKEDA PHARMACEUTICAL COMPANY (JP) 2008-06-12 US disclosed
EP-1852100-A1 METHOD FOR PRODUCING GRANULES Takeda Pharmaceutical Company Limited (JP) 2007-11-07 EP disclosed
US-20070141137-A1 Stable capsule preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-21 US disclosed
US-20070141137-A1 Stable capsule preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-21 US disclosed
EP-1144415-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2001-10-17 EP disclosed
WO-2000042045-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed